Tycho Baumann

7.8k total citations · 1 hit paper
49 papers, 1.5k citations indexed

About

Tycho Baumann is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Tycho Baumann has authored 49 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Genetics, 32 papers in Pathology and Forensic Medicine and 20 papers in Immunology. Recurrent topics in Tycho Baumann's work include Chronic Lymphocytic Leukemia Research (32 papers), Lymphoma Diagnosis and Treatment (32 papers) and Immunodeficiency and Autoimmune Disorders (15 papers). Tycho Baumann is often cited by papers focused on Chronic Lymphocytic Leukemia Research (32 papers), Lymphoma Diagnosis and Treatment (32 papers) and Immunodeficiency and Autoimmune Disorders (15 papers). Tycho Baumann collaborates with scholars based in Spain, Germany and Italy. Tycho Baumann's co-authors include Elı́as Campo, Neus Villamor, Christian Meisel, René Pschowski, Didier Keh, Steffen Weber‐Carstens, Petra Reinke, Hans‐Dieter Volk, Joerg C. Schefold and J. I. Gregor and has published in prestigious journals such as Nature, Blood and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Tycho Baumann

47 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Non-coding recurrent mutations in chronic lymphocytic leukaemia

2016 377 citations Neus Villamor, Marta Aymerich et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Tycho Baumann Spain	15	691	650	610	365	318	49	1.5k
Mikaël Roussel France	25	287 0.4×	942 1.4×	442 0.7×	339 0.9×	271 0.9×	76	1.8k
Joshua Gustine United States	18	1.1k 1.6×	486 0.7×	967 1.6×	222 0.6×	57 0.2×	67	1.6k
Masakazu Nitta Japan	21	386 0.6×	177 0.3×	149 0.2×	765 2.1×	137 0.4×	82	1.5k
Franck Trimoreau France	15	249 0.4×	261 0.4×	104 0.2×	271 0.7×	158 0.5×	50	1.0k
John L. Reagan United States	20	172 0.2×	453 0.7×	329 0.5×	403 1.1×	165 0.5×	107	1.5k
Cédric Garcia France	16	303 0.4×	175 0.3×	212 0.3×	171 0.5×	191 0.6×	39	996
Janet Valdez United States	17	1.1k 1.6×	608 0.9×	758 1.2×	223 0.6×	60 0.2×	42	1.7k
Sanna Siitonen Finland	23	103 0.1×	324 0.5×	125 0.2×	427 1.2×	185 0.6×	51	1.4k
Josef Birkmann Germany	22	254 0.4×	454 0.7×	373 0.6×	150 0.4×	42 0.1×	53	1.3k
Katsuji Shinagawa Japan	27	259 0.4×	428 0.7×	354 0.6×	591 1.6×	264 0.8×	108	1.9k

Countries citing papers authored by Tycho Baumann

Since Specialization

Citations

This map shows the geographic impact of Tycho Baumann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tycho Baumann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tycho Baumann more than expected).

Fields of papers citing papers by Tycho Baumann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tycho Baumann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tycho Baumann. The network helps show where Tycho Baumann may publish in the future.

Co-authorship network of co-authors of Tycho Baumann

This figure shows the co-authorship network connecting the top 25 collaborators of Tycho Baumann. A scholar is included among the top collaborators of Tycho Baumann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tycho Baumann. Tycho Baumann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Oliveira, Ana Carla, Tycho Baumann, Carlos Grande, et al.. (2025). Exploratory Study to Evaluate the Impact of Interim PET/CT Assessment in First-Line Follicular Lymphoma. Cancers. 17(7). 1065–1065.

Ubieto, Ana Jiménez, Margarita Rodríguez, Esther Parra-Mora, et al.. (2024). Clinical Utility of Ctdna Detection By NGS for Diagnosis of CNS Lymphoma. Blood. 144(Supplement 1). 6227–6227. 1 indexed citations

Baumann, Tycho, Riccardo Moia, Gianluca Gaïdano, et al.. (2021). Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. Leukemia. 35(8). 2325–2331. 10 indexed citations

Mozas, Pablo, Marc Sorigué, Alfredo Rivas‐Delgado, et al.. (2020). The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. European Journal Of Haematology. 106(3). 428–432. 1 indexed citations

Muntañola, Ana, Tycho Baumann, A Caballero, et al.. (2020). Results of R-ESHAP as salvage therapy in refractory/relapsed follicular lymphoma: a real-world experience on behalf of GELCAB group. Annals of Hematology. 99(7). 1627–1634. 3 indexed citations

Rovira, M, Neus Villamor, Francesc Cobo, et al.. (2020). Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation. Bone Marrow Transplantation. 55(9). 1860–1861. 2 indexed citations

Molica, Stefano, et al.. (2020). The BALL prognostic score identifies relapsed/refractory CLL patients who benefit the most from single-agent ibrutinib therapy. Leukemia Research. 95. 106401–106401. 5 indexed citations

Mozas, Pablo, Ferran Nadeu, Alfredo Rivas‐Delgado, et al.. (2020). Patterns of change in treatment, response, and outcome in patients with follicular lymphoma over the last four decades: a single-center experience. Blood Cancer Journal. 10(3). 31–31. 25 indexed citations

Delgado, Julio, Michael Doubek, Tycho Baumann, et al.. (2017). Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers ( IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL‐IPI. American Journal of Hematology. 92(4). 375–380. 66 indexed citations

10.

Dlouhy, Iván, Xavier Filella, Jordina Rovira, et al.. (2017). High serum levels of soluble interleukin-2 receptor (sIL2-R), interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF) are associated with adverse clinical features and predict poor outcome in diffuse large B-cell lymphoma. Leukemia Research. 59. 20–25. 38 indexed citations

11.

Pandzic, Tatjana, Jimmy Larsson, Liqun He, et al.. (2016). Transposon Mutagenesis Reveals Fludarabine Resistance Mechanisms in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 22(24). 6217–6227. 14 indexed citations

12.

Delgado, Julio, et al.. (2014). New treatment options for chronic lymphocytic leukemia. Expert Opinion on Pharmacotherapy. 15(6). 823–832. 6 indexed citations

13.

Delgado, Julio, Gabriela Ghita, Tycho Baumann, et al.. (2013). Rituximab-Based Chemoimmunotherapy Prolongs Survival of Patients With Chronic Lymphocytic Leukemia Independently of the Time of Administration. Clinical Lymphoma Myeloma & Leukemia. 14(1). 73–79. 3 indexed citations

14.

Ferrer, Gerardo, Alfons Navarro, Kate E Hodgson, et al.. (2013). MicroRNA expression in chronic lymphocytic leukemia developing autoimmune hemolytic anemia. Leukemia & lymphoma. 54(9). 2016–2022. 19 indexed citations

15.

Delgado, Julio, et al.. (2013). New Developments in Chronic Lymphocytic Leukaemia Diagnosis. European Oncology & Haematology. 9(2). 114–114. 1 indexed citations

16.

López, Cristina, Julio Delgado, Dolors Costa, et al.. (2012). Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes Chromosomes and Cancer. 51(9). 881–889. 44 indexed citations

17.

Delgado, Julio, Tycho Baumann, Gabriela Ghita, & Emili Montserrat. (2012). Chronic Lymphocytic Leukemia Therapy: Beyond Chemoimmunotherapy. Current Pharmaceutical Design. 18(23). 3356–3362. 4 indexed citations

18.

Nomdedéu, Meritxell, Margherita Maffioli, Xavier Calvo, et al.. (2011). Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation. Leukemia Research. 35(9). 1276–1278. 2 indexed citations

19.

Ferrer, Gerardo, Kate E Hodgson, Arturo Pereira, et al.. (2011). Combined analysis of levels of serum B-cell activating factor and a proliferation-inducing ligand as predictor of disease progression in patients with chronic lymphocytic leukemia. Leukemia & lymphoma. 52(11). 2064–2068. 7 indexed citations

20.

Meisel, Christian, Joerg C. Schefold, René Pschowski, et al.. (2009). Granulocyte–Macrophage Colony-stimulating Factor to Reverse Sepsis-associated Immunosuppression: A Double-Blind, Randomized, Placebo-controlled Multicenter Trial. American Journal of Respiratory and Critical Care Medicine. 180(7). 640–648. 455 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact